See every side of every news story
Published loading...Updated

New initiative aims to improve chronic kidney disease screening

  • Elanco Animal Health Incorporated will reduce its Board of Directors to 11 members by the 2025 Annual Meeting, with several members, including John P. Bilbrey, not seeking re-election at the end of their terms.
  • William F. Doyle has resigned from the Board effective immediately to enter into a research agreement with Elanco, focusing on innovative therapies for pets, including targeted gene therapy for chronic kidney disease.
  • Elanco signed a research agreement with WEDterinary LLC to develop novel therapies for chronic kidney disease in pets, aiming to enhance pet healthcare through innovative technologies.
Insights by Ground AI
Does this summary seem wrong?

47 Articles

All
Left
1
Center
15
Right
1
thepostandmail.comthepostandmail.com
+41 Reposted by 41 other sources
Center

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders:

·Columbia City, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 88% of the sources are Center
88% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

andoveradvertiser.co.uk broke the news in on Monday, March 17, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.